Cargando…
Triple hormone-receptor assay: a more accurate predictive tool for the treatment of advanced breast cancer?
In a group of 74 patients with advanced metastatic breast cancer, 57% of those with cytoplasmic oestrogen receptor activity in their tumours (REC+) showed a clinical response to endocrine therapy. Of 51 patients whose tumour was assayed for both REC and cytoplasmic progesterone (RPC) activity, 9/12...
Autores principales: | Barnes, D. M., Skinner, L. G., Ribeiro, G. G. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1979
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2010127/ https://www.ncbi.nlm.nih.gov/pubmed/230853 |
Ejemplares similares
-
Serum oestradiol-17 beta, testosterone, luteinizing hormone and follicle-stimulating hormone in males with breast cancer.
por: Ribeiro, G. G., et al.
Publicado: (1980) -
Hormones and Breast Cancer
por: Skinner, L. G.
Publicado: (1976) -
Hormones, Receptors and Breast Cancer
por: Barnes, D. M.
Publicado: (1979) -
Triple Targeting of Breast Tumors Driven by Hormonal Receptors and HER2
por: Shagisultanova, Elena, et al.
Publicado: (2022) -
Gonadotropin-releasing hormone receptor inhibits triple-negative breast cancer proliferation and metastasis
por: Chen, Cai-Ping, et al.
Publicado: (2022)